Brought to you by 
FOPO nets $112.8mm for Kythera Biopharmaceuticals
03 Jun 2021
Executive Summary
In the company's first financing since completing its IPO last year, Kythera Biopharmaceuticals Inc. netted $112.8mm through the follow-on public offering of 2.6mm common shares at $45.75. The company will use the money to continue developing Phase III ATX101 as an injectable to reduce submental fat (commonly called “double chin”), and to file the NDA.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FOPO nets $112.8mm for Kythera Biopharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice